One or two intact local summaries. No averaged regimen, patient-specific dose or automatic source preference.
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
An RX mirror and its underlying label are not independent clinical confirmations.
An acceptable baseline renal PK profile does not authorize continuing treatment through immune-mediated kidney injury.
What to reconcile: Grade toxicity separately and apply the current label hold, steroid and discontinuation criteria.
Open this note and its source referenceseGFR >=26 mL/min/1.73 m2 studied; dialysis not established.
Dialysis evidence: No dialysis regimen established in selected content
| Situation | Source-specific guidance |
|---|---|
| Baseline renal PK | Studied eGFR >=26 mL/min/1.73 m2; not a dialysis protocol. |
| Nephritis: grade 2 or 3 creatinine increase | Withhold; apply the full resumption criteria. |
| Nephritis: grade 4 creatinine increase | Permanently discontinue. |
Baseline eGFR at least 26 mL/min/1.73 m2 did not meaningfully affect exposure. This does not waive nephritis precautions. For nephritis with renal dysfunction, withhold for grade 2 or 3 creatinine increases and permanently discontinue for grade 4. Resume only after improvement to grade 0-1 and steroid taper. Permanently discontinue if resolution is not achieved within 12 weeks of starting steroids or prednisone-equivalent dosing cannot fall below 10 mg/day within 12 weeks. No dialysis regimen is established by the selected PK analysis.
RDM71-retifanlimab-zynyz-label-1 · Source locator: Section 12.3 and Table 1, nephritis with renal dysfunction
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
Pinned reference: https://globalrph.com/blogCalcs/renal-dosing-master/compare.php?id=retifanlimab-zynyz&s1=RDM71-retifanlimab-zynyz-label&h1=fdca62ab03e5073255194ca09b4387aee7634a2bf6ed8569d558df21df3e02d2